X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Domvanalimab is an Fc-silent investigational monoclonal antibody that is designed to bind to TIGIT, a protein receptor on immune cells that acts as a brake on the immune response.
Lead Product(s): Etrumadenant,Zimberelimab
Therapeutic Area: Oncology Product Name: AB154
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Arcus Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
Domvanalimab is an Fc-silent investigational monoclonal antibody that is designed to bind to TIGIT, a protein receptor on immune cells that acts as a brake on the immune response.
Lead Product(s): Etrumadenant,Zimberelimab
Therapeutic Area: Oncology Product Name: AB154
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Arcus Bioscience
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2022
Details:
ARC-7 and the ongoing ARC-10 Phase 3 registrational study will continue to enroll as planned, and preparations for additional Phase 3 studies are underway for domvanalimab-based combinations across various cancer types.
Lead Product(s): Domvanalimab,Zimberelimab,Etrumadenant
Therapeutic Area: Oncology Product Name: AB154
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
Details:
The Phase 1b clinical trial is a global multi-center, open-label trial of CERC-007 that will enroll around 12 subjects with active adult onset Still’s disease with a primal goal of the study will be to determine the safety and tolerability of CERC-007 in AOSD patients.
Lead Product(s): Eganelisib,Etrumadenant
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arcus Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2021
Details:
Under this agreement, Gilead Gains Broad Access to Arcus’s Clinical and Preclinical Pipeline of Immuno-Oncology Product Candidates that Target Critical Biological Pathways. Arcus to continue to independently conduct research on New Targets.
Lead Product(s): Zimberelimab,Etrumadenant,AB154
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $2,000.0 million Upfront Cash: $175.0 million
Deal Type: Collaboration May 27, 2020
Details:
Taiho’s in-licensing facilitates global development and commercialization of zimberelimab as a monotherapy and as a combination backbone for Arcus’s and Taiho’s oncology portfolios.
Lead Product(s): Zimberelimab,Etrumadenant,AB154
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Taiho Pharmaceutical
Deal Size: $275.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
